Consensus Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Real-time Estimate Cboe BZX Other stock markets 01:49:42 2024-04-23 pm EDT			5-day change	1st Jan Change
109.7 ^USD	+0.76%		+0.29%	-11.20%

Apr. 02	Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	MT
Apr. 02	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	CI

Evolution of the average Target Price on Jazz Pharmaceuticals plc

Price target over the last 5 years

History of analyst recommendation changes

11f0a8105a1b7a1faa70fe306078.uweW-OlMcAO6c26g-t0jmZROKmV6VTG0c24LY2A0yi8.im7-yLAECS7qPTv2mZdQ9-1jUlMMIGnjOVw6LRMMgQLtcqCTnR0Sc8s2GQ~9e845dc3bd997ebe42c2fe2f2ac179fe

Analyst Recommendations on Jazz Pharmaceuticals plc

JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating	Mar. 25	MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating	Mar. 20	MT
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating	Mar. 15	MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating	Mar. 14	MT
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating	Mar. 01	MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating	Mar. 01	MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating	Feb. 29	MT
Barclays Adjusts Jazz Pharmaceuticals' Price Target to $235 From $240, Keeps Overweight Rating	Jan. 29	MT
RBC Raises Price Target on Jazz Pharmaceuticals to $195 From $191, Keeps Outperform Rating	Jan. 03	MT
Baird Initiates Jazz Pharmaceuticals With Outperform Rating, Price Target is $160	Jan. 03	MT
UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $135 From $170	Nov. 27	MT
Needham Adjusts Jazz Pharmaceuticals' Price Target to $225 From $226, Maintains Buy Rating	Nov. 09	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $191 From $200, Keeps Outperform Rating	Nov. 09	MT
Raymond James Initiates Jazz Pharmaceuticals With Market Perform Rating	23-09-29	MT
Cantor Fitzgerald Cuts Jazz Pharmaceuticals' Price Target to $180 From $210, Keeps Overweight Rating	23-08-14	MT
Cantor Fitzgerald Cuts Price Target on Jazz Pharmaceuticals to $180 From $210, Maintains Overweight Rating	23-08-14	MT
RBC Trims Price Target on Jazz Pharmaceuticals to $201 From $203, Keeps Outperform Rating	23-08-10	MT
RBC Lifts Jazz Pharmaceuticals' Price Target to $203 From $202, Keeps Outperform Rating	23-07-07	MT
Needham Adjusts Price Target on Jazz Pharmaceuticals to $212 From $205, Maintains Buy Rating	23-05-11	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $202 From $207, Notes 'Soft' Q1 Revenue Amid Seasonality, Keeps Outperform Rating	23-05-11	MT
UBS Lowers Jazz Pharmaceuticals' Price Target to $182 From $194, Keeps Buy Rating	23-04-11	MT
RBC Capital Adjusts Jazz Pharmaceuticals Price Target to $207 From $203, Maintains Outperform Rating	23-04-06	MT
Fitch Affirms Jazz's IDR at 'BB-'; Outlook Positive	23-04-06	AQ
Goldman Sachs Adjusts Price Target on Jazz Pharmaceuticals to $212 From $190, Maintains Buy Rating	23-03-03	MT
Needham Adjusts Price Target on Jazz Pharmaceuticals to $205 From $210, Maintains Buy Rating	23-03-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

108.8 USD

Average target price

188.2 USD

Spread / Average Target

+72.94%

High Price Target

230 USD

Spread / Highest target

+111.34%

Low Price Target

121 USD

Spread / Lowest Target

+11.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Jazz Pharmaceuticals plc

JPMorgan Chase
Piper Sandler
Stifel Nicolaus
HC Wainwright
UBS
Barclays
Needham & Co.
RBC Capital Markets
Baird
Raymond James
Cantor Fitzgerald
Guggenheim
Goldman Sachs
BofA Securities
Morgan Stanley
SVB Securities LLC
BMO Capital
Truist Securities
SVB Leerink
Citigroup
J.P. Morgan Chase

Ratings for Jazz Pharmaceuticals plc

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar